The antidepressant effects of ketamine are confirmed by a new systematic review and meta-analysis

shutterstock_18453376

Helge Hasselmann summarises a new systematic review and meta-analysis, which confirms the antidepressant effects of ketamine.

[read the full story...]

One new drug a week: club drugs and novel psychoactive substances

shutterstock_36627214

Meg Fluharty summarises a recent report from the Royal College of Psychiatrists and explores why novel psychoactive substances and club drugs need a different response from UK treatment providers.

[read the full story...]

Ketamine for depression: new review highlights the need for an RCT

Helge Hasselmann reviews a new systematic review of ketamine for depression, which highlights the need for an RCT to provide reliable data on the safety, tolerability and best route of administration.

[read the full story...]

Ketamine for severe depression: what can we conclude from a small open label study?

shutterstock_170733776

Last week the media reported widely on a study of ketamine for depression (McShane et al, 2014). As usual the headlines made bold assertions, the Telegraph running with “Horse tranquilliser Ketamine could cure severe depression” (Knapton, 2014). But what did the paper authored by an Oxford group and published in the Journal of Psychopharmacology really [read the full story…]

Largest RCT so far suggests that ketamine may be useful in the acute treatment of refractory depression

shutterstock_137892476

Major depression is a serious mental illness that often does not respond to mainstream drug treatment (antidepressants). In addition, there is usually a delay of 2-6 weeks before mood improves significantly. In situations like this, when at least two conventional antidepressants have been tried without success, depression is considered treatment-resistant. While multiple different strategies to [read the full story…]